These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38654469)

  • 21. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d'Aosta Region, Italy, in the 2023-2024 Epidemic Season.
    Consolati A; Farinelli M; Serravalle P; Rollandin C; Apprato L; Esposito S; Bongiorno S
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study.
    Ezpeleta G; Navascués A; Viguria N; Herranz-Aguirre M; Juan Belloc SE; Gimeno Ballester J; Muruzábal JC; García-Cenoz M; Trobajo-Sanmartín C; Echeverria A; Martínez-Baz I; Vera-Punzano N; Casado I; López-Mendoza H; Ezpeleta C; Castilla J
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
    Dagan R; Hammitt LL; Seoane Nuñez B; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Chang Y; Currie A; Grenham A; Shroff M; Takas T; Mankad VS; Leach A; Villafana T
    J Pediatric Infect Dis Soc; 2024 Feb; 13(2):144-147. PubMed ID: 38219024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
    Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
    Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
    Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants.
    Jorgensen SCJ
    J Antimicrob Chemother; 2023 May; 78(5):1143-1149. PubMed ID: 36922390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants.
    Clegg L; Freshwater E; Leach A; Villafana T; Hamrén UW
    J Clin Pharmacol; 2024 May; 64(5):555-567. PubMed ID: 38294353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
    Wilkins D; Yuan Y; Chang Y; Aksyuk AA; Núñez BS; Wählby-Hamrén U; Zhang T; Abram ME; Leach A; Villafana T; Esser MT
    Nat Med; 2023 May; 29(5):1172-1179. PubMed ID: 37095249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.
    Ahani B; Tuffy KM; Aksyuk AA; Wilkins D; Abram ME; Dagan R; Domachowske JB; Guest JD; Ji H; Kushnir A; Leach A; Madhi SA; Mankad VS; Simões EAF; Sparklin B; Speer SD; Stanley AM; Tabor DE; Hamrén UW; Kelly EJ; Villafana T
    Nat Commun; 2023 Jul; 14(1):4347. PubMed ID: 37468530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nirsevimab: First Approval.
    Keam SJ
    Drugs; 2023 Feb; 83(2):181-187. PubMed ID: 36577878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).
    Coma E; Martinez-Marcos M; Hermosilla E; Mendioroz J; Reñé A; Fina F; Perramon-Malavez A; Prats C; Cereza G; Ciruela P; Pineda V; Antón A; Ricós-Furió G; Soriano-Arandes A; Cabezas C
    Arch Dis Child; 2024 Jun; ():. PubMed ID: 38857952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nirsevimab: A Review.
    Balbi H
    Pediatr Allergy Immunol Pulmonol; 2024 Mar; 37(1):3-6. PubMed ID: 38484270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding New Recommendations for Respiratory Syncytial Virus Prevention in Pregnancy.
    Horgan R; Hughes BL; Waller J; Hage Diab Y; Saade G
    Obstet Gynecol; 2024 Apr; 143(4):484-490. PubMed ID: 38330405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
    Domachowske JB; Chang Y; Atanasova V; Cabañas F; Furuno K; Nguyen KA; Banu I; Kubiak RJ; Leach A; Mankad VS; Shroff M; Takas T; Villafana T; Wählby Hamrén U
    J Pediatric Infect Dis Soc; 2023 Aug; 12(8):477-480. PubMed ID: 37466917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
    J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
    Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
    Front Immunol; 2022; 13():880368. PubMed ID: 35572550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
    Ektare V; Lang J; Choi Y; Finelli L
    Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
    Wilkins D; Langedijk AC; Lebbink RJ; Morehouse C; Abram ME; Ahani B; Aksyuk AA; Baraldi E; Brady T; Chen AT; Chi H; Choi EH; Cohen R; Danilenko DM; Gopalakrishnan V; Greenough A; Heikkinen T; Hosoya M; Keller C; Kelly EJ; Kragten-Tabatabaie L; Martinón-Torres F; de Los Santos AHM; Nunes MC; Palomino MA; Papenburg J; Pernica JM; Richmond P; Stein RT; Tuffy KM; Verwey C; Esser MT; Tabor DE; Bont LJ;
    Lancet Infect Dis; 2023 Jul; 23(7):856-866. PubMed ID: 36940703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.